Abdul-Rahman Toufik, Roy Poulami, Herrera-Calderón Ranferi Eduardo, Khidri Feriha Fatima, Omotesho Quadri Ajibola, Rumide Tolulope Sharon, Fatima Mahek, Roy Sakshi, Wireko Andrew Awuah, Atallah Oday, Roy Subham, Amekpor Felix, Ghosh Shankhaneel, Agyigra Isaac Aksavdwa, Horbas Viktoriia, Teslyk Tetiana, Bumeister Valentyna, Papadakis Marios, Alexiou Athanasios
Medical Institute, Sumy State University, Sumy, Ukraine.
Department of Medicine, North Bengal Medical College and Hospital, Siliguri, India.
Discov Oncol. 2024 May 23;15(1):181. doi: 10.1007/s12672-024-01007-y.
Breast cancer (BC) continues to be a significant global challenge due to drug resistance and severe side effects. The increasing prevalence is alarming, requiring new therapeutic approaches to address these challenges. At this point, Extracellular vesicles (EVs), specifically small endosome-released nanometer-sized EVs (SEVs) or exosomes, have been explored by literature as potential theranostics. Therefore, this review aims to highlight the therapeutic potential of exosomes in BC, focusing on their advantages in drug delivery and their ability to mitigate metastasis. Following the review, we identified exosomes' potential in combination therapies, serving as miRNA carriers and contributing to improved anti-tumor effects. This is evident in clinical trials investigating exosomes in BC, which have shown their ability to boost chemotherapy efficacy by delivering drugs like paclitaxel (PTX) and doxorubicin (DOX). However, the translation of EVs into BC therapy is hindered by various challenges. These challenges include the heterogeneity of EVs, the selection of the appropriate parent cell, the loading procedures, and determining the optimal administration routes. Despite the promising therapeutic potential of EVs, these obstacles must be addressed to realize their benefits in BC treatment.
由于耐药性和严重的副作用，乳腺癌（BC）仍然是一个重大的全球性挑战。其发病率不断上升，令人担忧，需要新的治疗方法来应对这些挑战。目前，细胞外囊泡（EVs），特别是小的由内体释放的纳米级EVs（SEVs）或外泌体，已被文献探索为潜在的治疗诊断方法。因此，本综述旨在突出外泌体在乳腺癌中的治疗潜力，重点关注其在药物递送方面的优势及其减轻转移的能力。在综述之后，我们确定了外泌体在联合治疗中的潜力，作为miRNA载体并有助于提高抗肿瘤效果。这在研究乳腺癌中外泌体的临床试验中很明显，这些试验表明它们能够通过递送紫杉醇（PTX）和阿霉素（DOX）等药物来提高化疗疗效。然而，EVs转化为乳腺癌治疗受到各种挑战的阻碍。这些挑战包括EVs的异质性、合适亲本细胞的选择、装载程序以及确定最佳给药途径。尽管EVs具有有前景的治疗潜力，但必须解决这些障碍才能实现它们在乳腺癌治疗中的益处。
